Treatment Willingness and Importance of Skin Clearance for Patients With Chronic Hand Eczema.

Background: Chronic hand eczema (CHE) has a significant negative impact on quality of life and a high disease burden.

Objective: To investigate the importance of skin clearance and daily time trade off (dTTO) in adult patients with CHE.

Methods: Patients with CHE from the Danish Skin Cohort were sent a digital survey regarding demographics, lifestyle factors, CHE characteristics, importance of obtaining skin clearance, and dTTO.

Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study.

Background: Conjunctivitis is among the most frequent adverse events (AEs) emerged in clinical trials for all biologic drugs approved for atopic dermatitis (AD). However, real-world comparative data on the incidence, risk factors, and management of conjunctivitis remain limited.

Objective: We aimed to compare the incidence, clinical features, and management of conjunctivitis in patients with moderate-to-severe AD treated with dupilumab or tralokinumab in a real-life setting.

Effectiveness of Tralokinumab for Moderate-to-Severe Atopic Dermatitis Involving the Head-and-Neck Area: A Multicenter Retrospective Cohort Study.

Atopic dermatitis (AD) affecting the head and neck (H&N) area poses a clinical challenge due to the unique anatomical and physiological features of this region. Despite its well-documented impact on quality of life (QoL), evidence on the effectiveness of tralokinumab in treating AD specifically in the H&N area remains limited. To assess the clinical outcomes of tralokinumab in AD patients with H&N involvement, informing clinical decision-making and improving patient care.

JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis).

Introduction: Janus kinase (JAK) inhibitors are effective systemic treatments for moderate-to-severe atopic dermatitis (AD), rapidly controlling symptoms and improving quality of life. However, the impact of body mass index (BMI) on therapeutic response remains unclear.

Methods: This multicenter retrospective study analyzed data from 388 adult AD patients treated with upadacitinib, abrocitinib, or baricitinib across 25 Italian dermatology centers between May 2022 and July 2024.

Therapeutic Outcomes Across JAK Inhibitors in Prurigo Nodularis.

Background: Prurigo nodularis (PN) is a debilitating skin condition. When inadequate disease control is achieved or other systemic therapies are contraindicated, JAK inhibitors may be considered although real-world evidence remains limited.

Objective: To investigate clinical findings and treatment outcomes among patients diagnosed with PN and undergoing JAK inhibitors in real-world setting.

European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol.

Introduction: Atopic dermatitis (AD) is a chronic, relapsing, heterogeneous skin disease affecting 2%-7% of adults, with roughly 30% having moderate-to-severe disease. AD symptoms, like intense itching and skin pain, carry a substantial disease burden that negatively impacts patients' quality of life (QoL) and psychosocial well-being. Lebrikizumab is a novel, high-affinity monoclonal antibody that selectively binds to and neutralises interleukin-13 with high potency.

Clinical Course of Atopic Dermatitis after Dupilumab Discontinuation: A Multicenter Real-World Study.

Introduction: Limited data exist on the clinical course of atopic dermatitis (AD) after the discontinuation of dupilumab. This study aims to assess disease progression following dupilumab discontinuation.

Methods: A multicenter, retrospective study was conducted on 208 patients with severe AD who discontinued dupilumab for reasons unrelated to inefficacy.

Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study.

Introduction: Evaluating the real-world effectiveness, safety, and tolerability of targeted biologic and non-biologic therapies in patients with atopic dermatitis (AD) treated in routine clinical practice remains crucial. In this international, multicenter, retrospective, comparative study we aimed to evaluate the 52-week effectiveness, safety, and tolerability of dupilumab, tralokinumab, and upadacitinib in patients with AD aged ≥ 12 years.

Methods: Effectiveness was assessed at weeks 16, 24, and 52 using Eczema Area and Severity Index (EASI) and itch Numerical Rating Scale (NRS) scores.

Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study-IL AD (Italian Landscape Atopic Dermatitis).

Atopic dermatitis (AD) prevalence in elderly patients is increasing. Clinically, elderly AD may present with atypical phenotypes, making the diagnosis difficult. Moreover, treatment challenges arise due to treatment-resistance, comorbidities, polypharmacy, and contraindications to existing therapies.

The Italian Trend of Contact Allergy to 2-Hydroxyethyl Methacrylate: Is the Current European Legislation Working?

Background: (Meth)acrylates are well-known causes of allergic contact dermatitis, and nail products are the major source of exposure, especially in a non-occupational setting. In 2020, the European legislation restricted 2-hydroxyethyl methacrylate (2-HEMA) only in nail cosmetics to professional use.

Objective: To investigate the Italian prevalence trend of positive patch test reactions to 2-HEMA, the best marker for delayed hypersensitivity to (meth)acrylates.

Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study.

Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease worldwide. In the difficult-to-treat BP or if standard therapies are contraindicated, the use of biologics may be also considered although there is no strong evidence supporting their use. This study aimed to investigate clinical and diagnostic findings as well as treatment outcomes among patients diagnosed with BP and undergoing omalizumab or dupilumab in a real-world setting.

Risk Assessment in Atopic Dermatitis: Guidance from a Multidisciplinary Expert Panel.

Guidelines recommend that patients with severe atopic dematitis (AD) be treated with Janus kinase inhibitors (JAKi). Recently, the safety of JAKi as a class was reviewed by the European Medicines Agency, leading to a modification of the Summaries of Product Characteristics. For upadacitinib, changes involve reduced posology and restriction of its use to patients with no other alternative amongst the elderly and those at an increased risk of major adverse cardiovascular events (MACE), cancer and venous thromboembolism (VTE).

Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes.

: Tralokinumab, a fully human monoclonal antibody targeting IL-13, has shown efficacy and safety in clinical trials and real-life studies for atopic dermatitis (AD). However, data on its effectiveness across AD phenotypes are limited. : A multicentric study evaluated tralokinumab's efficacy over 52 weeks in 416 severe AD patients.

Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study.

Background: Atopic dermatitis (AD) is a chronic inflammatory skin condition that significantly impairs the quality of life. Recent advancements in systemic therapies, such as Janus kinase (JAK) inhibitors, offer very effective new treatment options. However, concerns regarding potential adverse events, including cardiovascular and thromboembolic risk, have emerged from clinical studies and call for further real-life investigations.

Efficacy and drug survival of tralokinumab in patients with severe atopic dermatitis: an 18-month multicentre study.

Background: Tralokinumab has demonstrated efficacy in the treatment of atopic dermatitis (AD) in clinical trials and real-world settings. However, there are limited data regarding the long-term use of tralokinumab in real-world settings. Here, we report the findings of a multicentre Italian study conducted to address this knowledge gap.

Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study.

Baricitinib, a JAK 1/2 inhibitor, is approved for treating severe alopecia areata (AA). This study aimed to evaluate the long-term effectiveness and safety of baricitinib in a real-world setting over 52 weeks. This multicenter retrospective study included 96 adult patients diagnosed with severe AA from 11 Italian Dermatology Units.